MicroRNA-221/222 confers tamoxifen resistance in breast cancer by targeting p27Kip1
- PMID: 18708351
- PMCID: PMC2573063
- DOI: 10.1074/jbc.M804612200
MicroRNA-221/222 confers tamoxifen resistance in breast cancer by targeting p27Kip1
Abstract
We explored the role of microRNAs (miRNAs) in acquiring resistance to tamoxifen, a drug successfully used to treat women with estrogen receptor-positive breast cancer. miRNA microarray analysis of MCF-7 cell lines that are either sensitive (parental) or resistant (4-hydroxytamoxifen-resistant (OHT(R))) to tamoxifen showed significant (>1.8-fold) up-regulation of eight miRNAs and marked down-regulation (>50%) of seven miRNAs in OHT(R) cells compared with parental MCF-7 cells. Increased expression of three of the most promising up-regulated (miR-221, miR-222, and miR-181) and down-regulated (miR-21, miR-342, and miR-489) miRNAs was validated by real-time reverse transcription-PCR. The expression of miR-221 and miR-222 was also significantly (2-fold) elevated in HER2/neu-positive primary human breast cancer tissues that are known to be resistant to endocrine therapy compared with HER2/neu-negative tissue samples. Ectopic expression of miR-221/222 rendered the parental MCF-7 cells resistant to tamoxifen. The protein level of the cell cycle inhibitor p27(Kip1), a known target of miR-221/222, was reduced by 50% in OHT(R) cells and by 28-50% in miR-221/222-overexpressing MCF-7 cells. Furthermore, overexpression of p27(Kip1) in the resistant OHT(R) cells caused enhanced cell death when exposed to tamoxifen. This is the first study demonstrating a relationship between miR-221/222 expression and HER2/neu overexpression in primary breast tumors that are generally resistant to tamoxifen therapy. This finding also provides the rationale for the application of altered expression of specific miRNAs as a predictive tamoxifen-resistant breast cancer marker.
Figures



Similar articles
-
Anti-microRNA-222 (anti-miR-222) and -181B suppress growth of tamoxifen-resistant xenografts in mouse by targeting TIMP3 protein and modulating mitogenic signal.J Biol Chem. 2011 Dec 9;286(49):42292-42302. doi: 10.1074/jbc.M111.270926. Epub 2011 Oct 18. J Biol Chem. 2011. Retraction in: J Biol Chem. 2018 Mar 9;293(10):3588. doi: 10.1074/jbc.W118.002430. PMID: 22009755 Free PMC article. Retracted.
-
Downregulation of miR-342 is associated with tamoxifen resistant breast tumors.Mol Cancer. 2010 Dec 20;9:317. doi: 10.1186/1476-4598-9-317. Mol Cancer. 2010. PMID: 21172025 Free PMC article.
-
miR-449a Suppresses Tamoxifen Resistance in Human Breast Cancer Cells by Targeting ADAM22.Cell Physiol Biochem. 2018;50(1):136-149. doi: 10.1159/000493964. Epub 2018 Oct 2. Cell Physiol Biochem. 2018. PMID: 30278449
-
Differential microRNA profiles between fulvestrant-resistant and tamoxifen-resistant human breast cancer cells.Anticancer Drugs. 2018 Jul;29(6):539-548. doi: 10.1097/CAD.0000000000000623. Anticancer Drugs. 2018. PMID: 29557813
-
MiR 221/222 as New Players in Tamoxifen Resistance.Curr Pharm Des. 2016;22(46):6946-6955. doi: 10.2174/1381612822666161102100211. Curr Pharm Des. 2016. PMID: 27809747 Review.
Cited by
-
The regulation of RNA metabolism in hormone signaling and breast cancer.Mol Cell Endocrinol. 2021 Jun 1;529:111221. doi: 10.1016/j.mce.2021.111221. Epub 2021 Mar 10. Mol Cell Endocrinol. 2021. PMID: 33711334 Free PMC article. Review.
-
Genome-wide screen for aberrantly expressed miRNAs reveals miRNA profile signature in breast cancer.Mol Biol Rep. 2013 Mar;40(3):2175-86. doi: 10.1007/s11033-012-2277-5. Epub 2012 Nov 30. Mol Biol Rep. 2013. PMID: 23196705
-
Decoding the usefulness of non-coding RNAs as breast cancer markers.J Transl Med. 2016 Sep 15;14:265. doi: 10.1186/s12967-016-1025-3. J Transl Med. 2016. PMID: 27629831 Free PMC article. Review.
-
Tamoxifen Resistance: Emerging Molecular Targets.Int J Mol Sci. 2016 Aug 19;17(8):1357. doi: 10.3390/ijms17081357. Int J Mol Sci. 2016. PMID: 27548161 Free PMC article. Review.
-
The Roles of MicroRNAs in Breast Cancer.Cancers (Basel). 2015 Apr 9;7(2):598-616. doi: 10.3390/cancers7020598. Cancers (Basel). 2015. PMID: 25860815 Free PMC article. Review.
References
-
- Early Breast Cancer Trialists' Collaborative Group (2005) Lancet 365 1687-1717 - PubMed
-
- Shou, J., Massarweh, S., Osborne, C. K., Wakeling, A. E., Ali, S., Weiss, H., and Schiff, R. (2004) J. Natl. Cancer Inst. 96 926-935 - PubMed
-
- Carlomagno, C., Perrone, F., Gallo, C., De Laurentiis, M., Lauria, R., Morabito, A., Pettinato, G., Panico, L., D'Antonio, A., Bianco, A. R., and De Placido, S. (1996) J. Clin. Oncol. 14 2702-2708 - PubMed
-
- Lewis, J. S., and Jordan, V. C. (2005) Mutat. Res. 591 247-263 - PubMed
-
- Croce, C. M. (2008) N. Engl. J. Med. 358 502-511 - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Molecular Biology Databases
Research Materials
Miscellaneous